OAC1
Based on 1 publication(s) in Google Scholar
OAC1 is a potent Oct4 activator. OAC1 activates Oct4 and Nanog promoters and enhances induced pluripotent stem cells (iPSC) formation. OAC1 activates OCT4 through upregulation of HOXB4 expression. OAC1 increases transcription of the Oct4-Nanog-Sox2 triad and TET1. OAC1 facilitates the reprogramming of cells by enhancing efficiency and shortening the reprogramming time.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.85%
- CAS. Nr.: 300586-90-7
- Formel: C14H11N3O
- Molecular Weight:237.26
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Transcription Factor-Targeted Library
HY-L090
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) OAC1
More
Biologische Aktivität
|
TET1 |
OAC1 (10 μM; 7 d) enhances reprogramming efficiency. OAC1 increases induced pluripotent stem cells (iPSC) generation from mouse embryonic fibroblasts (MEFs) and accelerates the appearance of iPSC-like colonies[1].
OAC1 (1 μM; 2 d; human IMR90 fibroblast cells) activates endogenous Oct4, Nanog, Sox2, and Tet1 expression[1].
OAC1 (500 nM; 4 d; CD34+ cells) increases numbers of phenotypic hematopoietic stem cells (HSC) and functional Hematopoietic progenitor cells (HPC)[2].
OAC1 (500 nM; 4 d; CD34+ cells) activates OCT4 through upregulation of HOXB4 expression to expand hematopoietic stem cells (HSC)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD34+ cells from human cord blood
-
Concentration:500 nM
-
Incubation Time:4 days
-
Result:Increased the numbers of CD34+CD38- cells.
Increased the number of Lin-CD34+CD38-CD45RA-CD90+CD49f+ cells.
Increased in the number of phenotypic hematopoietic stem cells (HSC) compared to control vectors.
Enhanced expansion of HPC with both full and suboptimal cytokine doses in the expansion and colony forming phases.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Irradiated NSG mice with OAC1 or vehicle control treated CB CD34+ cells within 24h after irradiation[2]
-
Dosage:16 weeks
-
Administration:Subcutaneous injection OAC1(500 nM) treated CB CD34+ cells
-
Result:Increased cord blood (CB) cells in primary recipients, compared to the vehicle control group, with the board increase for human B cells, T cells, and myeloid cells in the bone marrow (BM) of primary recipients, resulting in a significant expansion of SRC numbers.
Chemical Information
-
CAS. Nr. 300586-90-7
-
Appearance Solid
-
Molecular Weight 237.26
-
Formel C14H11N3O
-
Color Light yellow to gray
-
SMILES
O=C(NC1=CC2=C(NC=C2)C=N1)C3=CC=CC=C3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
DMSO : ≥ 40 mg/mL (168.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Li W, et, al. Identification of Oct4-activating compounds that enhance reprogramming efficiency. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):20853-8. [Content Brief]
[2]. Huang X, et, al. Activation of OCT4 enhances ex vivo expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression. Leukemia. 2016 Jan;30(1):144-53. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.2148 mL | 21.0739 mL | 42.1479 mL | 105.3696 mL |
| 5 mM | 0.8430 mL | 4.2148 mL | 8.4296 mL | 21.0739 mL | |
| 10 mM | 0.4215 mL | 2.1074 mL | 4.2148 mL | 10.5370 mL | |
| 15 mM | 0.2810 mL | 1.4049 mL | 2.8099 mL | 7.0246 mL | |
| 20 mM | 0.2107 mL | 1.0537 mL | 2.1074 mL | 5.2685 mL | |
| 25 mM | 0.1686 mL | 0.8430 mL | 1.6859 mL | 4.2148 mL | |
| 30 mM | 0.1405 mL | 0.7025 mL | 1.4049 mL | 3.5123 mL | |
| 40 mM | 0.1054 mL | 0.5268 mL | 1.0537 mL | 2.6342 mL | |
| 50 mM | 0.0843 mL | 0.4215 mL | 0.8430 mL | 2.1074 mL | |
| 60 mM | 0.0702 mL | 0.3512 mL | 0.7025 mL | 1.7562 mL | |
| 80 mM | 0.0527 mL | 0.2634 mL | 0.5268 mL | 1.3171 mL | |
| 100 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL | 1.0537 mL |
OAC1 Related Classifications
HY-12303 Related Classifications
Powered by Bioz